A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

Adding the drug enzalutamide to standard hormone therapy reduced the risk of premature death by more than 40% in patients ...

Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death ...

In hormone-sensitive prostate cancer, an alternative dosing of docetaxel plus Nubeqa and ADT was associated with improvements in side effect rates.

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...

My doctor was of the opinion that over-medicalisation of patients was a common problem, and that a high PSA reading might ...

Two cancer experts go head to head, arguing the case for and against a targeted prostate cancer screening programme.

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Researchers have been working on ways to improve prostate cancer diagnosis and deaths for years. Being one of the most common ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...